Siderocalin fusion proteins enable a new 86Y/90Y theranostic approach

被引:1
|
作者
Cosby, Alexia G. [1 ]
Arino, Trevor [1 ,2 ]
Bailey, Tyler A. [1 ,2 ]
Buerger, Matthew [3 ]
Woods, Joshua J. [1 ]
Quintana, Luis M. Aguirre M. [1 ]
Vasquez, Jennifer V. Alvarenga V. [1 ]
Wacker, Jennifer N. [1 ]
Gaiser, Alyssa N. [1 ]
Strong, Roland K. [3 ]
Abergel, Rebecca J. [1 ,2 ]
机构
[1] Lawrence Berkeley Natl Lab, Chem Sci Div, Berkeley, CA 94720 USA
[2] Univ Calif Berkeley, Dept Nucl Engn, Berkeley, CA 94720 USA
[3] Fred Hutchinson Canc Ctr, Div Basic Sci, Seattle, WA 98109 USA
来源
RSC CHEMICAL BIOLOGY | 2023年 / 4卷 / 08期
关键词
COMPLEXES; 3,4,3-LI(1,2-HOPO); RECOGNITION; STABILITY;
D O I
10.1039/d3cb00050h
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mammalian protein siderocalin binds bacterial siderophores and their iron complexes through cation-pi and electrostatic interactions, but also displays high affinity for hydroxypyridinone complexes of trivalent lanthanides and actinides. In order to circumvent synthetic challenges, the use of siderocalin-antibody fusion proteins is explored herein as an alternative targeting approach for precision delivery of trivalent radiometals. We demonstrate the viability of this approach in vivo, using the theranostic pair Y-90 (beta(-), t(1/2) = 64 h)/Y-86 (beta(+), t(1/2) = 14.7 h) in a SKOV-3 xenograft mouse model. Ligand radiolabeling with octadentate hydroxypyridinonate 3,4,3-LI(1,2-HOPO) and subsequent protein binding were achieved at room temperature. The results reported here suggest that the rapid non-covalent binding interaction between siderocalin fusion proteins and the negatively charged Y(iii)-3,4,3-LI(1,2-HOPO) complexes could enable purification-free, cold-kit labeling strategies for the application of therapeutically relevant radiometals in the clinic.
引用
收藏
页码:587 / 591
页数:5
相关论文
共 50 条
  • [1] The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y
    Roesch, Frank
    Herzog, Hans
    Qaim, Syed M.
    PHARMACEUTICALS, 2017, 10 (02)
  • [2] Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?
    Walrand, Stephan
    Flux, Glenn D.
    Konijnenberg, Mark W.
    Valkema, Roelf
    Krenning, Eric P.
    Lhommel, Renaud
    Pauwels, Stanislas
    Jamar, Francois
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : 57 - 68
  • [3] Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?
    Stephan Walrand
    Glenn D. Flux
    Mark W. Konijnenberg
    Roelf Valkema
    Eric P. Krenning
    Renaud Lhommel
    Stanislas Pauwels
    Francois Jamar
    European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 57 - 68
  • [4] 86Y and 89Zr as PET imaging surrogates for 90Y:: A comparative study
    Avila-Rodriguez, M. A.
    Selwyn, R. G.
    Converse, A. K.
    Nickles, R. J.
    MEDICAL PHYSICS, 2006, 854 : 45 - +
  • [5] Modular syntheses of H4octapa and H2dedpa, and yttrium coordination chemistry relevant to 86Y/90Y radiopharmaceuticals
    Price, Eric W.
    Cawthray, Jacqueline F.
    Adam, Michael J.
    Orvig, Chris
    DALTON TRANSACTIONS, 2014, 43 (19) : 7176 - 7190
  • [6] 86Y/90Y-labeled ultrasmall porous silica nanoparticles with enhanced pharmacokinetics for cancer theranostics
    Cai, Weibo
    Ferreira, Carolina
    Goel, Shreya
    Aluicio-Sarduy, Eduardo
    Engle, Jonathan
    NUCLEAR MEDICINE AND BIOLOGY, 2022, 108 : S160 - S161
  • [7] Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies
    Egesta Lopci
    Arturo Chiti
    Maria Rita Castellani
    Giovanna Pepe
    Lidija Antunovic
    Stefano Fanti
    Emilio Bombardieri
    European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 28 - 40
  • [8] 90Y Labelled Cathepsin Activity-Based Probe for Cancer Theranostic
    Ma, Xiaowei
    Li, Xiang
    Wang, Shuailiang
    Wang, Jing
    Wang, Yunhua
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [9] Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies
    Lopci, Egesta
    Chiti, Arturo
    Castellani, Maria Rita
    Pepe, Giovanna
    Antunovic, Lidija
    Fanti, Stefano
    Bombardieri, Emilio
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : 28 - 40
  • [10] A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin™
    Garmestani, K
    Milenic, DE
    Plascjak, PS
    Brechbiel, MW
    NUCLEAR MEDICINE AND BIOLOGY, 2002, 29 (05) : 599 - 606